Dorff, T. B., Appleman, L. J., Lin, C., Lee, J. L., Tran, B., Fischer, S., Danila, D., Gokani, P., Gallent, B., Pook, D. W. (2026). XALience: A phase 3, open-label, multicenter, randomized study of xaluritamig plus abiraterone vs investigator’s choice in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps5144